Illumina (ILMN)
(Delayed Data from NSDQ)
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Here's Why You Should Hold on to Haemonetics Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.
Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply
by Zacks Equity Research
Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.
Abbott Stock Down on Urgent Field Safety Notice for TactiCath
by Zacks Equity Research
Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.
LabCorp's New Website Offers Patients Coronavirus Trial Details
by Zacks Equity Research
LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.
Digital Transformation Stocks to Stay Hot in 2020: 5 Picks
by Sreoshi Bera
The coronavirus pandemic has forced businesses to make digital transformations. As automation holds the key, these five stocks are poised to rally further.
Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt
by Zacks Equity Research
Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.
Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
Why Is Illumina (ILMN) Up 13.8% Since Last Earnings Report?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
VRTX vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. ILMN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
Illumina (ILMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 30.16% and 0.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Illumina (ILMN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.
10 Stocks Leading the Rally in the S&P 500 ETF
by Sweta Killa
Signs of a slowdown in the number of hospitalizations and intensive-care admissions in New York and Europe has led to optimism over the reopening of the economy soon and improving activity in the near future.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Stock Moves -1.75%: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session.